Therapy of Myelofibrosis: Where We Are and What Next

Treatment of myelofibrosis has greatly improved since the approval of the Janus kinase (JAK) inhibitor ruxolitinib more than 5 years ago. However, it has become clear that inhibition of JAK-STAT signaling alone is not a curative strategy. Therefore, rational combination of ruxolitinib with agents targeting other signaling pathways that are dysregulated in myelofibrosis is an attractive strategy. Several clinical studies testing ruxolitinib in combination with other agents are now underway. The rationale for and early results of clinical studies of ruxolitinib-containing combination therapies will be discussed.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Srdan Verstovsek Source Type: research